Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial Combining Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA)

NCT05638698 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT05638698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05638698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial Combining Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA)
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 15, 2022
Completion date
December 31, 2025
Enrollment
24 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer